FDA CRL - MedicaSafe, Inc.

MedicaSafe, Inc. has received a Complete Response Letter from the FDA regarding its drug-device combination product application (NDA 220184). The FDA determined the application cannot be approved in its current form due to concerns spanning product quality, manufacturing processes, and device safety. Key issues include deficiencies in software, electrical safety, and electromagnetic compatibility. Furthermore, Human Factors validation testing revealed that users might incorrectly orient drug cartridges in the dispensing device, which could result in a failure to deliver medication and subsequent opioid withdrawal. Under the regulatory framework of the Federal Food, Drug, and Cosmetic Act and associated federal regulations, the FDA is requiring a Risk Evaluation and Mitigation Strategy (REMS). This program is mandatory to mitigate the serious risks of accidental overdose, misuse, and abuse. The REMS must include a Medication Guide and specific monitoring requirements to ensure safe use. To move forward, MedicaSafe must submit a formal REMS proposal, revise product labeling to include cartridge orientation instructions, provide a comprehensive safety update incorporating recent clinical data, and resubmit the proposed proprietary name. The company has one year to address these deficiencies or request an extension. Approval is withheld until all safety, quality, and risk management requirements are fully resolved.